Product Pathways - Growth Factors/Cytokines
Human Interleukin-4 (hIL-4) #8919
|8919LC||50 µg (With Carrier)||---||In Stock||---|
|8919LF||50 µg (Carrier Free)||---||In Stock||---|
|8919SC||10 µg (With Carrier)||---||In Stock||---|
|8919SF||10 µg (Carrier Free)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant human IL-4 (hIL-4) His25-Ser153 (Accession #AF395008) was expressed in human 293 cells at Cell Signaling Technology.
Recombinant hIL-4 does not have a Met on the amino terminus and the nonglycosylated protein has a calculated MW of 14,963. DTT-reduced and non-reduced protein migrate as larger 20 kDa polypeptides due to glycosylation, with non-reduced having slightly greater mobility due to an intramolecular cystine. The expected amino-terminal HKCDI of recombinant hIL-4 was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-4. All lots are greater than 98% pure.
The bioactivity of recombinant hIL-4 was determined in a TF-1 cell proliferation assay. The ED50 of each lot is between 80-250 pg/ml.
The purity of recombinant hIL-4 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hIL-4 and staining overnight with Coomassie Blue.
The proliferation of TF-1 cells treated with increasing concentrations of hIL-4 was assessed. After 48 hour treatment with hIL-4, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
Western blot analysis of extracts from TF-1 cells, untreated or treated with hIL-4 for 20 minutes, using Phospho-Stat6 (Tyr641) (C11A12) Rabbit mAb Antibody #9364 (upper) and Stat6 Antibody #9362 (lower).
Less than 0.01 ng endotoxin/1 μg hIL-4.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-4. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
IL-4 is produced by T cells, NK T cells, γδ cells, and mast cells (1). Target cells include B cells, T cells, and macrophages (1). IL-4 induces differentiation of naive T cells into the TH2 phenotype. IL-4 also promotes B cell proliferation, antibody isotype switching and expression of other TH2 cytokines including IL-5 and IL-9. IL-4 induced TH2 polarization is important in developing humoral immunity against extracellular pathogens (1) and is involved in the development of allergy and asthma (2). IL-4 binds to two distinct receptors, the type I receptor and type II receptor. Type I receptor is a heterodimer consisting of IL-4Rα chain and the common gamma chain, γc (3,4). Type II receptor, which is shared with IL-13, is a heterodimer of IL-4Rα and IL-13Rα1. Signaling initiated via type I receptor results in the activation of Jak1/Stat6, Jak3 and the PI3K/Akt pathways (3). The type II receptor activates the Jak1/Stat6 and the Tyk2/Stat3 pathways (3).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.